5 recruiting, 3 not yet recruiting, 2 unknown, 1 active not recruiting. 7 Phase 2, 2 Phase 3, 2 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 4, Not yet recruiting 2, Completed 1 |
| Phase 3 | 2 | Active not recruiting 1, Unknown 1 |
| Phase 4 | 2 | Not yet recruiting 1, Unknown 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Carboplatin or cisplatin: new trials by email Literature Review of Carboplatin or cisplatin trials Research Report on Carboplatin or cisplatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer Quad Shot Radiotherapy, Tislelizumab, Carboplatin or cisplatin - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2026-10-10 | 2026-09-29 |
| A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer benmelstobart, Anlotinib, Carboplatin or cisplatin - SCLC, Extensive Stage | Phase 2 | Not yet recruiting | Yayi He | 33 | 2026-04-20 | 2026-04-20 |
| Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer Benmelstobart, Anlotinib, Carboplatin or cisplatin - Extensive-stage Small Cell Lung Cancer | Phase 4 | Not yet recruiting | Peking Union Medical College Hospital | 50 | 2025-04-15 | 2025-04-23 |
| Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy JS207, Pemetrexed, Carboplatin or cisplatin - Non-squamous Non-small Cell Lung Cancer | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 78 | 2025-03-30 | 2026-05-18 |
| A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer SKB264, Pembrolizumab, pemetrexed - Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 432 | 2024-10-30 | 2026-07-08 |
| Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC Tislelizumab, Etoposide, Carboplatin or Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Second Hospital of Shanxi Medical University | 40 | 2024-08-01 | 2026-04-24 |
| Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer Tislelizumab, Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC), Carboplatin or Cisplatin - Non-small-cell Lung Cancer (NSCLC) | Phase 4 | Unknown | The Affiliated Hospital of Qingdao University | 30 | 2024-01-18 | 2024-04-10 |
| Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer Carboplatin or cisplatin, Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar, Bevacizumab or biosimilar - Recurrent Ovarian Carcinoma | Not applicable | Recruiting | The University of Hong Kong | 18 | 2023-11-01 | 2025-06-11 |
| MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer Durvalumab, Monalizumab, Carboplatin or Cisplatin - Small Cell Lung Cancer, SCLC | Phase 2 | Recruiting | Hirva Mamdani | 84 | 2023-09-26 | 2026-04-29 |
| A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC) Pacliltaxel or Nab-paclitaxel, Carboplatin or Cisplatin, Pembrolizumab - Metastatic Squamous Non-Small Cell Lung Carcinoma | Phase 2 | Recruiting | University of Illinois at Chicago | 36 | 2022-12-28 | 2026-01-08 |
| Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Pembrolizumab, Carboplatin or Cisplatin, Docetaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Completed | Peking Union Medical College Hospital | 28 | 2020-06-01 | 2023-10-10 |
| Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC Atezolizumab(Tecentriq), Pemetrexed, Bevacizumab - Non-small Cell Lung Cancer | Phase 3 | Unknown | Samsung Medical Center | 228 | 2019-08-27 | 2023-04-03 |
Carcinoma, Non-Small-Cell Lung (4) · Small Cell Lung Carcinoma (4) · Esophageal Squamous Cell Carcinoma (1) · Ovarian Neoplasms (1)
Peking Union Medical College Hospital (2) · Hirva Mamdani (1) · Samsung Medical Center (1) · Second Hospital of Shanxi Medical University (1) · Shanghai Junshi Bioscience Co., Ltd. (1) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (1) · The Affiliated Hospital of Qingdao University (1) · The University of Hong Kong (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · University of Illinois at Chicago (1) · Yayi He (1)
China (7) · United States (2) · Hong Kong (1) · South Korea (1)
Gang Jin, Dr. (1) · Hirva Mamdani, MD (1) · Ka Yu Tse (1) · Li Li, MD (1) · Myung-Ju Ahn, MD (1) · Weihua Wang, Doctor (1) · Wenjie Jiao, PhD (1)